Burkitt Lymphoma
Showing 1 - 25 of 5,429
Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult Trial in Zhuhai (Thiotepa,
Recruiting
- Burkitt Lymphoma
- +2 more
- Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
-
Zhuhai, Guangdong, ChinaThe Fifth Affiliated Hospital of Sun Yat-sen University
Sep 25, 2023
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)
Not yet recruiting
- Non Hodgkin Lymphoma
- +5 more
- Pirtobrutinib
- LV20.19 CAR T cells
- (no location specified)
Aug 4, 2023
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Recruiting
- Diffuse Large Cell Lymphoma
- +4 more
- Vincristine
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)
Completed
- HIV
- Burkitt's Lymphoma
- Induction Phase
- +4 more
-
Aviano (PN), Italy
- +7 more
Aug 2, 2022
GastroIntestinal Cancer in Children and Adolescents
Active, not recruiting
- Gastrointestinal Cancer
- +6 more
-
Leiden, South-Holland, Netherlands
- +1 more
Jan 11, 2023
Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt
Not yet recruiting
- Relapsed/Refractory Waldenstrom Macroglobulinemia
- +3 more
- Brexucabtagene Autoleucel
- +2 more
- (no location specified)
Sep 8, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))
Not yet recruiting
- Leukemia
- +12 more
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- (no location specified)
Mar 20, 2023
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma Trial in Mwanza (mNavigator)
Active, not recruiting
- Burkitt Lymphoma
- +2 more
- mNavigator
-
Mwanza, Lake Zone, TanzaniaBugando Medical Centre
Mar 7, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,
Not yet recruiting
- Acute Myelogenous Leukemia
- +17 more
- Peripheral Blood Stem Cell Transplant
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Mar 27, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia Trial in Tampa (Fludarabine, Melphalan, Total
Active, not recruiting
- Acute Myeloid Leukemia
- +17 more
- Fludarabine
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +10 more
- Bortezomib
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +11 more
- Zilovertamab vedotin
-
Duarte, California
- +13 more
Jan 12, 2023
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma Trial run by the
Active, not recruiting
- AIDS-Related Burkitt Lymphoma
- +5 more
- Prednisone
- +7 more
-
Bethesda, MarylandNCI Lymphoid Malignancies Branch
Jul 31, 2022
